CNS pipeline · person
Sharon Mates, PhD
Board member of Seaport Therapeutics. Co-founder, Chairman and CEO of Intra-Cellular Therapies (developer of CAPLYTA/lumateperone), which she led from its 2002 founding until its 2025 acquisition by Johnson & Johnson.
- 2 companies
Courtesy Seaport Therapeutics
Current roles
- Intra-Cellular Therapies, Inc.Co-Founder · Founder2002–present
- Intra-Cellular Therapies, Inc.Chairman and Chief Executive Officer · Executive2013–present
- Intra-Cellular Therapies, Inc.Chairman of the Board (Director) · Board2013–present
- Seaport Therapeutics, Inc.Board Member · Board
Appears with
People sharing a company with Sharon.
- Antony Loebel · Seaport Therapeutics, Inc.
- Bob Hombach · Seaport Therapeutics, Inc.
- Daphne Zohar · Seaport Therapeutics, Inc.
- David Wheadon · Seaport Therapeutics, Inc.
- Denice Torres · Seaport Therapeutics, Inc.
- E. Rene Salas · Intra-Cellular Therapies, Inc.
- Eric Green · Seaport Therapeutics, Inc.
- Jason Pitts · Seaport Therapeutics, Inc.
- Jim Healy · Seaport Therapeutics, Inc.
- Joel S. Marcus · Intra-Cellular Therapies, Inc.
- Lana Gladstein · Seaport Therapeutics, Inc.
- Lauren White · Seaport Therapeutics, Inc.
- Lawrence J. Hineline · Intra-Cellular Therapies, Inc.
- Mark Neumann · Intra-Cellular Therapies, Inc.
- Michael Chen · Seaport Therapeutics, Inc.
- Michael I. Halstead · Intra-Cellular Therapies, Inc.
- Robert L. Van Nostrand · Intra-Cellular Therapies, Inc.
- Rory B. Riggs · Intra-Cellular Therapies, Inc.
- Sandi Peterson · Seaport Therapeutics, Inc.
- Steven Paul · Seaport Therapeutics, Inc.
- Suresh Durgam · Intra-Cellular Therapies, Inc.
People and affiliation data assembled from public company disclosures, SEC filings, and conference materials — every record source-cited under psychiatrist-authored guardrails.